ArticleJID innovations : skin science from molecules to population health2026
Initial preclinical investigation of aclarubicin treatment in primary cutaneous T-cell lymphoma cells.
Article in JID innovations : skin science from molecules to population health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Better therapeutic agents are needed in the treatment of advanced cutaneous T-cell lymphomas. Anthracyclines, including doxorubicin, are such drugs, but they are associated with cardiotoxicity that limits treatment. Aclarubicin is an anthracycline that acts by chromatin damage only and does not show any dose-accumulated cardiotoxicity. We compared the cytotoxicity of different anthracyclines that either induce DNA breaks and/or nucleosome eviction on primary ex vivo patient material. Both cutaneous T-cell lymphoma tumor cells and normal CD4 T cells experience cytotoxicity at the same concentration of anthracyclines. Under a 2-hour pulse exposure that mimics the serum pharmacokinetics of these drugs, aclarubicin was less toxic, with an 8-20-fold lower half-maximal inhibitory concentration than those of the other anthracyclines tested, yet it demonstrated superior ex vivo cytotoxicity under T-cell activation. Aclarubicin should be considered for further preclinical and clinical evaluation in cutaneous T-cell lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.